RxDoctor Payments Data

Ashlyn Morehouse

Nurse Practitioner · Johnson City, TNNPI 1962126128

Payments from drug & device makers

$2,371in general payments, 2019–2025

Across 170 payments — averaging $13.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$532
  • AbbVie$532
  • Braeburn Inc.$191
  • Otsuka America Pharmaceutical, Inc.$185
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$150
  • Neurocrine Biosciences, Inc.$124
  • plus $656 from 12 others

What the payments were for

  • Food & beverage$2,371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,371 in reported general payments places this provider in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$10,174
Medicare patients
21
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$34,372
JardianceEmpagliflozin23$15,373
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,358
MounjaroTirzepatide12$12,665
SymbicortBudesonide/Formoterol Fumarate35$8,043
Spiriva HandihalerTiotropium Bromide14$7,358
VascepaIcosapent Ethyl17$5,294
Gabapentin273$2,880
Albuterol Sulfate HfaAlbuterol Sulfate112$2,432
Pregabalin114$2,022
Hydroxyzine Hcl40$1,308
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,291
Ondansetron OdtOndansetron55$1,112
Duloxetine Hcl73$1,017
Ibuprofen40$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$112$34,37233 claims
Lilly USA, LLCMounjaro$18$12,66512 claims
AstraZenecaSymbicort$92$8,04335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →